Myriad Genetics will support the post-marketing regulatory development of Clovis Oncology‘s drug Rubraca (rucaparib) to treat women with BRCA-positive advanced ovarian cancer who have already received two or more chemotherapies. The U.S. Food and Drug ... Read more